Pulmonx backs FY25 revenue view $96M-$98M, consensus $96.98M

The company said, “Pulmonx (LUNG) reaffirms full year 2025 revenue guidance to be in the range of $96 million to $98 million, anticipating growth generally in line with our prior expectations. The Company expects gross margin for the full year 2025 to be approximately 74%. Pulmonx continues to expect total operating expenses for the full year 2025 to fall within the range of $133 million to $135 million, inclusive of approximately $22 million of non-cash stock-based compensation. The Company’s reaffirmed guidance does not currently reflect any potential impact from future tariffs or trade policy changes, or their effects on the global macroeconomic environment, including foreign currency fluctuations, which cannot be predicted at this time.”